VAGHI, GLORIA
 Distribuzione geografica
Continente #
NA - Nord America 1.082
AS - Asia 626
EU - Europa 466
SA - Sud America 99
Continente sconosciuto - Info sul continente non disponibili 70
AF - Africa 32
Totale 2.375
Nazione #
US - Stati Uniti d'America 1.053
SG - Singapore 195
CN - Cina 177
IT - Italia 95
VN - Vietnam 86
RU - Federazione Russa 82
BR - Brasile 78
HK - Hong Kong 74
DE - Germania 66
IE - Irlanda 65
FR - Francia 38
GB - Regno Unito 37
FI - Finlandia 28
IN - India 22
BD - Bangladesh 21
ZA - Sudafrica 19
CA - Canada 13
AT - Austria 9
JP - Giappone 9
MX - Messico 8
NL - Olanda 8
IQ - Iraq 7
PL - Polonia 7
ES - Italia 6
ID - Indonesia 6
CO - Colombia 5
AR - Argentina 4
CZ - Repubblica Ceca 4
MA - Marocco 4
SE - Svezia 4
CH - Svizzera 3
EC - Ecuador 3
EE - Estonia 3
JM - Giamaica 3
PK - Pakistan 3
TN - Tunisia 3
TR - Turchia 3
UZ - Uzbekistan 3
VE - Venezuela 3
AL - Albania 2
BH - Bahrain 2
CL - Cile 2
GR - Grecia 2
JO - Giordania 2
KG - Kirghizistan 2
LV - Lettonia 2
MY - Malesia 2
PE - Perù 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
CM - Camerun 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KZ - Kazakistan 1
LU - Lussemburgo 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
Totale 2.305
Città #
San Jose 142
Council Bluffs 101
Singapore 100
Ashburn 96
Dallas 73
Hong Kong 72
Dublin 65
Beijing 57
Chandler 51
Los Angeles 45
Munich 27
Boardman 24
Lauterbourg 23
Milan 22
Hanoi 20
Ho Chi Minh City 20
Santa Clara 20
Johannesburg 18
Shanghai 18
New York 17
Helsinki 16
Moscow 14
Rome 13
Chicago 12
Frankfurt am Main 12
São Paulo 12
Turku 12
Buffalo 10
Columbus 10
London 10
Redondo Beach 10
Atlanta 9
Brooklyn 9
Phoenix 9
Tokyo 9
Orem 8
Düsseldorf 7
Warsaw 7
Falkenstein 6
Lawrence 6
Medford 6
Mexico City 6
Princeton 6
The Dalles 6
Boston 5
Chennai 5
Da Nang 5
Belo Horizonte 4
Cuiabá 4
Dhaka 4
Medellín 4
Nuremberg 4
Poplar 4
Stockholm 4
Amsterdam 3
Cremona 3
Denver 3
Hefei 3
Hyderabad 3
Manchester 3
Modena 3
Mumbai 3
Ninh Bình 3
Piscataway 3
Portsmouth 3
San Francisco 3
Secaucus 3
Serra 3
Seveso 3
Toronto 3
Vienna 3
Wilmington 3
Amman 2
Ankara 2
Athens 2
Baghdad 2
Bishkek 2
Bologna 2
Brasília 2
Campinas 2
Chandigarh 2
Changsha 2
City of London 2
Cormano 2
Denpasar 2
Dongguan 2
Edinburgh 2
Elk Grove Village 2
Fortaleza 2
Frascati 2
Guangzhou 2
Guayaquil 2
Ha Long 2
Haiphong 2
Houston 2
Kingston 2
La Tronche 2
Lahore 2
Lima 2
Louisville 2
Totale 1.389
Nome #
Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview 175
Correlation of frontal atrophy and CSF tau levels with neuropsychiatric symptoms in patients with cognitive impairment: a memory clinic experience 136
COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course 119
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial 118
Expression of selected microRNAs in migraine: A new class of possible biomarkers of disease? 107
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study 106
Differences in Trunk Acceleration-Derived Gait Indexes in Stroke Subjects with and without Stroke-Induced Immunosuppression 99
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 98
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study (The Journal of Headache and Pain, (2021), 22, 1, (114), 10.1186/s10194-021-01333-4) 97
Potential Contribution of Hypertension to Evolution of Chronic Migraine and Related Mechanisms 96
BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in the CLINICAL PICTURE of DEMENTIA 93
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 91
Expression of miR-155 in monocytes of people with migraine: association with phenotype, disease severity and inflammatory profile 90
null 80
Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study 80
High-frequency episodic migraine: Time for its recognition as a migraine subtype? 79
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study 72
Pearls & Oy-sters: Marionette Walk in Parkinson Disease 69
Expression of miR-155 in monocytes of people with migraine: association with phenotype, disease severity and inflammatory profile 69
Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study 65
Oculo-vestibular signs in experimentally induced migraine attacks: an exploratory analysis 65
Searching for the Predictors of Response to BoNT-A in Migraine Using Machine Learning Approaches 61
Redefining migraine prevention: Early treatment with anti-CGRP monoclonal antibodies enhances response in the real world 60
Who cares about migraine? Pathways and hurdles in the European region - access to care III 45
Clinical and instrumental gait phenotyping in people with GLUT-1 deficiency syndrome 38
Setting higher standards for migraine prevention: A position statement of the International Headache Society 20
Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis 15
miR-382-5p and miR-34a in migraine: Expression in monocytes and a post-hoc exploratory comparison with expression in peripheral blood mononuclear cells 15
Childhood traumas delineate a distinct psychological and clinical profile in adults with migraine: The hidden burden 12
Peripheral Endocannabinoid Components and Lipid Plasma Levels in Patients with Resistant Migraine and Co-Morbid Personality and Psychological Disorders: A Cross-Sectional Study 11
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study) 11
null 11
Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache 9
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study) 9
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study) 8
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine 8
Peripheral Endocannabinoid Components and Lipid Plasma Levels in Patients with Resistant Migraine and Co-Morbid Personality and Psychological Disorders: A Cross-Sectional Study 6
Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort 6
Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC): Results of a randomized controlled trial 6
Exploring the Association of Migraine Susceptibility SNPs With the Risk of Chronic Migraine 5
Evidence-based guidelines for the pharmacological treatment of migraine, summary version 5
Evidence-based guidelines for the pharmacological treatment of migraine 5
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort 5
Totale 2.375
Categoria #
all - tutte 10.264
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.264


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 0 0 0 0 0 0 3 1 3 1 13
2022/2023151 13 11 0 10 13 11 2 13 68 3 6 1
2023/202494 7 10 2 1 8 12 2 15 1 6 14 16
2024/2025513 11 13 9 2 11 71 55 28 120 34 68 91
2025/20261.151 95 57 99 123 154 37 172 66 122 88 105 33
2026/2027424 37 103 174 110 0 0 0 0 0 0 0 0
Totale 2.375